Fate Therapeutics Inc [NASDAQ: FATE] gained 6.62% or 0.1 points to close at $1.61 with a heavy trading volume of 6082652 shares.
It opened the trading session at $1.52, the shares rose to $1.66 and dropped to $1.43, the range by which the price of stock traded the whole day. The daily chart for FATE points out that the company has recorded 75.08% gains over the past six months.
If we look at the average trading volume of 1.79M shares, FATE reached to a volume of 6082652 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Fate Therapeutics Inc [FATE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FATE shares is $4.39 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FATE stock is a recommendation set at 2.18. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Fate Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 18, 2024. While these analysts kept the previous recommendation, Piper Sandler raised their target price from $4 to $6. The new note on the price target was released on June 17, 2024, representing the official price target for Fate Therapeutics Inc stock. Previously, the target price had yet another raise to $6, while Wells Fargo analysts kept a Equal Weight rating on FATE stock. On January 24, 2023, analysts decreased their price target for FATE shares from 115 to 7.
The Price to Book ratio for the last quarter was 0.71, with the Price to Cash per share for the same quarter was set at 1.93.
Trading performance analysis for FATE stock
Fate Therapeutics Inc [FATE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 33.06. With this latest performance, FATE shares gained by 61.00% in over the last four-week period, additionally plugging by 75.08% over the last 6 months – not to mention a drop of -2.42% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FATE stock in for the last two-week period is set at 78.46, with the RSI for the last a single of trading hit 0.1369, and the three-weeks RSI is set at 0.1103 for Fate Therapeutics Inc [FATE]. The present Moving Average for the last 50 days of trading for this stock 1.0831, while it was recorded at 1.4260 for the last single week of trading, and 1.1784 for the last 200 days.
Fate Therapeutics Inc [FATE]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Fate Therapeutics Inc [FATE] shares currently have an operating margin of -2097.24% and a Gross Margin at -89.27%. Fate Therapeutics Inc’s Net Margin is presently recorded at -2025.05%.
Fate Therapeutics Inc (FATE) Capital Structure & Debt Analysis
According to recent financial data for Fate Therapeutics Inc. ( FATE), the Return on Equity (ROE) stands at -52.11%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -38.10%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Fate Therapeutics Inc’s Return on Invested Capital (ROIC) is -50.89%, showcasing its effectiveness in deploying capital for earnings.
Fate Therapeutics Inc (FATE) Efficiency & Liquidity Metrics
Based on Fate Therapeutics Inc’s (FATE) latest financial statements, the Debt-to-Equity Ratio is 0.31%, indicating its reliance on debt financing relative to shareholder equity.
Fate Therapeutics Inc (FATE) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Fate Therapeutics Inc. (FATE) effectively leverages its workforce, generating an average of -$947624.31 per employee. The company’s liquidity position is robust, with a Current Ratio of 8.04% and a Quick Ratio of 8.04%, indicating strong ability to cover short-term liabilities.
Fate Therapeutics Inc [FATE]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Fate Therapeutics Inc posted -0.4/share EPS, while the average EPS was predicted by analysts to be reported at -0.41/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FATE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Fate Therapeutics Inc go to 16.70%.
An analysis of Institutional ownership at Fate Therapeutics Inc [FATE]
There are presently around $78.59%, or 79.95%% of FATE stock, in the hands of institutional investors. The top three institutional holders of FATE stocks are: REDMILE GROUP, LLC with ownership of 13.17 million shares, which is approximately 11.2107%. VANGUARD GROUP INC, holding 10.57 million shares of the stock with an approximate value of $$34.67 million in FATE stocks shares; and VANGUARD GROUP INC, currently with $$33.18 million in FATE stock with ownership which is approximately 8.6118%.
